In different disease models such as prostate cancer (PCa) and glioblastoma (GBM) models, TLK1 depletion has been shown to elicit DNA damage response, and, therefore TLK1 forms a druggable target [51,52,53] (Figure 2). This evidence concerns the gene TLK1 and glioblastoma.